In this edition, European commission approves Beovu for DME, choroidal vascularity index linked with geographic atrophy progression, intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy, and more.
Read the full coverage here:
Susvimo noninferior to monthly ranibizumab with similar efficacy
European Commission approves Beovu for DME
Intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy
Teprotumumab may provide better outcomes than IV methylprednisolone in thyroid eye disease
Choroidal vascularity index linked with geographic atrophy progression
References:
Healio Interviews
Holekamp NM, et al. Ophthalmology. 2022;doi:10.1016/j.ophtha.2021.09.016.
Newman N, et al. The Phase III REFLECT Trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON). Presented at: American Academy of Neurology Annual Meeting; April 2-7, 2022; Seattle.
Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305.
